Latest News

A novel all-antibody therapy shows remarkable efficacy and safety in elderly patients with newly diagnosed multiple myeloma, achieving high response rates and MRD negativity.

A new trial shows promising results for combining niraparib and dostarlimab in treating triple-negative breast cancer with BRCA mutations.

Premenopausal women with early breast cancer favor GnRHa therapy for fertility preservation during chemotherapy, with varying acceptance based on age and hormone receptor status.

A RAD51-based assessment identifies HER2-negative breast cancer patients likely to benefit from olaparib, enhancing treatment selection and outcomes.

Real acupuncture significantly enhances cognitive health in breast cancer survivors, outperforming usual care and showing promise over sham treatments.

New data from the TRIFOUR trial show that nadunolimab plus chemotherapy offers no significant survival benefit in metastatic triple-negative breast cancer.

Discover the latest breakthroughs in oncology from major conferences, including significant findings in breast cancer and multiple myeloma treatments.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

GC012F/AZD0120 CAR T-cell therapy shows 100% response rate in newly diagnosed multiple myeloma, offering hope for diverse patient groups.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

Alpelisib plus fulvestrant significantly improves progression-free survival in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

FDA and EMA approve AVC-203, a groundbreaking CAR-T therapy targeting B-cell malignancies, promising enhanced safety and scalability for patients.